Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease

Journal of the American Society of Nephrology

Volumn 18, Issue 5, 2007, Pages 1525-1533

  Matsumoto, Yuriko ^a   Ueda, Seiji ^a   Yamagishi, Sho Ichi ^a   Matsuguma, Kyoko ^a   Shibata, Ryo ^a   Fukami, Kei ^a   Matsuoka, Hidehiro ^a   Imaizumi, Tsutomu ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; DIMETHYLARGININASE; HYDRALAZINE; N(G),N(G) DIMETHYLARGININE; RNA DIRECTED DNA POLYMERASE; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM; BLOOD PRESSURE; CAPILLARY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE; MALE; NEPHRECTOMY; NONHUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; UPREGULATION;

EID: 34248136447     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006070696     Document Type: Article

References (47)

1. Cooke JP: Dose ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20: 2032-2037, 2000
2. Ueda S, Yamagishi S, Kaneyuki U, Okuda S: Asymmetric dimethylarginine (ADMA) and cardiovascular disease. Vasc Dis Prev 3: 291-295, 2006
3. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 29: 242-247, 1997
4. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 99: 1141-1146, 1999
5. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27: 765-769, 2004
6. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
7. Zoccali C, Bode-Boger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
8. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso S, Laaksonen R: Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128, 2001
9. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res 97: e53-e59, 2005
10. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki Utako, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S: Molecular mechanism for elevation of asymmetric dimethylarginine (ADMA) and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17: 2176-2183, 2006
11. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005
12. Ravani P, Tripepu G, Mallberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455, 2005
13. Zoccali C, Kielstein JT: Asymmetric dimethylarginine: A new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 15: 314-320, 2006
14. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002
15. Erdely A, Wagner L, Muller V, Szabo A, Baylis C: Protection of Wistar Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthesis. J Am Soc Nephrol 14: 2526-2533, 2003
16. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-2578, 1998
17. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T: Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circ Res 92: 226-233, 2003
18. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T: Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: A novel anti-oxidative mechanism of PEDF. Cell Tissue Res 320: 437-445, 2005
19. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95: 2068-2074, 1997
20. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function: A meta-analysis. Nephrol Dial Transplant 21: 2446-2451, 2006
21. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H: Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17: 1128-1134, 2006
22. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG: Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290: H209-H216, 2006
23. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001
24. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C: Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144, 2003
25. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M: TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of Adriamycin nephropathy. Kidney Int 45: 525-536, 1994
26. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86: 453-462, 1990
27. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70: 781-787, 2006
28. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176, 2002
29. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R; CREED Investigators: Asymmetric dimethylarginine, c-reactive protein, and carotid intimamedia thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496, 2002
30. Closs EI, Basha FZ, Habermeier A, Forstermann U: Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65-73, 1997
31. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 108: 3042-3047, 2003
32. Fine LG, Orphanides C, Norman JT: Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int 65[Suppl]: S74-S78, 1998
33. Nangaku M: Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006
34. Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, Suki WN, Truong LD: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor. Hum Pathol 31: 1491-1497, 2000
35. Suschek CV, Schnorr O, Hemmrich K, Aust O, Klotz LO, Sies H, Kolb-Bachofen V: Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation 107: 2607-2614, 2003
36. Ziche M, Parenti A, Ledda F, Dell'Era P, Granger HJ, Maggi CA, Presta M: Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 80: 845-852, 1997
37. Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, Losordo DW, Isner JM: Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 19: 1156-1161, 1999
38. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P: Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308: 984-989, 2003
39. Kostourou V, Robinson SP, Cartwright JE, Whitley GS: Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 87: 673-680, 2002
40. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, Cooke JP: Overexpression of dimethylarginine dimemylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111: 1431-1438, 2005
41. Zhang B, Liang X, Shi W, Ye Z, He C, Hu X, Liu S: Role of impaired peritubular capillary and hypoxia in progressive interstitial fibrosis after 56 subtotal nephrectomy of rats. Nephrology (Carlton) 10: 351-357, 2005
42. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A: Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32: 273-279, 1998
43. Stehouwer CD, Smulders YM: Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 17: 2106-2111, 2006
44. Arcos MI, Fujihara CK, Sesso A, de Almeida Prado EB, de Almeida Prado MJ, de Nucci G, Zatz R: Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol 279: F1060-F1066, 2000
45. Sharma M, McCarthy ET, Savin VJ, Lianos EA: Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 68: 2735-2744, 2005
46. Okubo K, Hayashi K, Wakino S, Matsuda H, Kubota E, Honda M, Tokuyama H, Yamamoto T, Kajiya F, Saruta T: Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 28: 181-189, 2005
47. Cross JM, Donald A, Vallance PJ, Deanfield JE, Woolfson RG, MacAllister RJ: Dialysis improves endothelial function in humans. Nephrol Dial Transplant 16: 1823-1829, 2001